Navigation Links
Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
Date:7/19/2012

BEDFORD, Mass., July 19, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX) announced today the pricing of its private placement of $1.0 billion in aggregate principal amount of its 6.25% Senior Notes due 2020 (the "Notes"). The offering is expected to close concurrently with the completion of Hologic's acquisition of Gen-Probe Incorporated (NASDAQ: GPRO). The acquisition is subject to the satisfaction of certain customary closing conditions, including obtaining the approval of Gen-Probe's stockholders. Gen-Probe has scheduled a Special Meeting of Stockholders for July 31, 2012 to vote on the pending acquisition and Hologic expects to close the acquisition on or about August 1, 2012.

Separately, Hologic announced that it has received expected pricing on its anticipated $2.80 billion of Senior Secured Credit Facilities to be obtained in connection with its acquisition of Gen-Probe. Those facilities are anticipated to comprise of the following:

  • $300 million revolving credit facility, initially at LIBOR plus 3.00%, due 2017;
  • $1.0 billion tranche A term loan facility, initially at LIBOR plus 3.00%, due 2017; and
  • $1.50 billion tranche B term loan facility, at LIBOR plus 3.50%, with a LIBOR floor of 1.00%, due 2019.

Hologic also expects to have the right to elect, from time to time, to have all or a portion of the facilities accrue interest at a base rate, to be defined, plus an applicable base rate margin. The margin applicable to the revolving credit facility and the tranche A loan facility is subject to adjustment based on changes in the total net leverage ratio to be specified in the definitive documentation for these facilities. The allocation of the principal amount, interest and the determination of the purchase price of the Senior Secured Credit Facilities are subject to change in limited circumstances, and the closing of the facilities is contingent on the satisfaction of certain conditions set forth in the definitive documentation for the facilities, including the closing of the Gen-Probe acquisition and there not having occurred, since December 31, 2011, an Acquired Business Material Adverse Effect (as defined in the definitive documentation for the facilities). The Senior Secured Credit Facilities are expected to close concurrently with the completion of Hologic's acquisition of Gen-Probe.

Based upon the pricing of the Notes and the expected pricing of the Senior Secured Credit Facilities, Hologic anticipates that the initial blended interest yield on the Company's total financing for the Gen-Probe acquisition will be approximately 4.80%, including the amortization of the original issue discount (OID) and excluding the impact of deferred financing costs.

Hologic intends to use the net proceeds from the Notes offering, together with amounts drawn under its new Senior Secured Credit Facilities and available cash, to acquire Gen-Probe and pay related fees and expenses.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States in accordance with Regulation S under the Securities Act. Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Notes.

About Hologic:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:
This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements with respect to the anticipated timing and completion of the Company's acquisition of Gen-Probe, and the anticipated closing and terms of the Company's financing for that acquisition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: the ability of Hologic to consummate the proposed acquisition of Gen-Probe in a timely manner or at all; satisfaction of the conditions precedent to consummation of the proposed acquisition, including the approval by Gen-Probe's stockholders; uncertainties relating to litigation, including pending and future Gen-Probe shareholder lawsuits related to the proposed acquisition; and the successful completion of all the other anticipated financing arrangements for the acquisition including the completion and funding of Hologic's proposed Senior Secured Credit Facilities, which may, among other things, be adversely affected by changes in prevailing credit markets (which have been subject to significant volatility), or adverse changes to Hologic's business or prospects, and the Company's ability to satisfy its conditions precedent for the closing of the issuance of its Notes. The risks included above are not exhaustive. Other factors that could adversely affect Hologic's business and prospects are described in the filings made by Hologic with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Contacts:

Hologic Investor Contact:                                                           
Deborah R. Gordon                                                                        
Vice President, Investor Relations                                           
(781) 999-7716                                                                                  
Deborah.Gordon@hologic.com                                                 

Hologic Media Contact:
Joele Frank / Andrew Siegel / Nicholas Lamplough
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449


'/>"/>
SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 2012
3. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
4. Hologic, Inc. Announces Note Offering
5. Hologic And Gen-Probe Provide Update On Pending Transaction
6. Hologic and Gen-Probe Announce Clearance from German Federal Cartel Office for Hologics Acquisition of Gen-Probe
7. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Misonix Announces New Distribution Agreement For Panama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., ... pleased to announce the appointment of George M. Rapier, ... San Antonio, TX , WellMed is one of ... 200,000 patients and HMO members in Texas ... in 1990 out of his own internal medicine practice, he ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. ... utilizing human amniotic membrane and other birth tissues, human ... to develop and market advanced products and therapies, announced ... Markets, 2016 Global Healthcare Conference in New ... and CEO, Michael J. Senken , Chief Financial ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
(Date:2/11/2016)... ... 2016 , ... The Chartis Group, a national advisory services ... the “2015/2016 Best in KLAS: Software and Services” report in two categories: IT ... insights firm on a global mission to improve healthcare delivery by amplifying the ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader ... to announce the promotions of Allison Kelly to executive vice president of the ... vice president of North American capital sales, and Wendy Oseas to vice president ...
Breaking Medicine News(10 mins):